TAA Polyepitope DNA-Based Vaccines: A Potential Tool for Cancer Therapy
Figure 1
Polyepitope DNA-based cancer vaccines and cross-antigen presentation. After injection of the recombinant polyepitope DNA vaccine into myocyte or keratinocytes, antigenic materials is transferred to dendritic cells (antigen cross-presentation).
We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.
